MDL-101 (Modalis Therapeutics)

MDL-101 is an investigational epigenome editing therapy developed by Modalis Therapeutics for the treatment of LAMA2-related congenital muscular dystrophy (LAMA2-CMD). Utilizing the proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) platform, MDL-101 employs a catalytically inactive Cas9 (dCas9) fused to a trans-activating domain. Delivered via a muscle-specific adeno-associated virus (AAV) vector and driven by a muscle-specific promoter, the system uses a guide RNA to target the LAMA1 gene, a highly homologous sister gene to the disease-causing LAMA2. By inducing the expression of LAMA1 in muscle tissues, MDL-101 aims to compensate for the loss of LAMA2 function, potentially providing a one-time, durable treatment for patients. It has received Orphan Drug and Rare Pediatric Disease designations from the FDA.